Profile your compound using clinical endpoints
Explore Gubra’s spirometry-confirmed BLEO-IPF mouse models
Gubra offers advanced bleomycin-induced and spirometry-confirmed mouse models of Idiopathic Pulmonary Fibrosis (IPF). The combination of lung function and respiratory capacity testing and an automated AI-based histopathology pipeline enables objective and accurate analysis of drug effects.
Explore our ERS 2026 research
Download Gubra’s latest posters
Download our latest scientific posters and explore our latest preclinical research and findings, and discover how we can advance your drug development with preclinical bleomycin-induced mouse models featuring hallmarks of lung dysfunction confirmed by spirometry and whole-body plethysmography.
Discover more from our IPF research
Related Publications
Standard Study Outlines
Cloud-based brain data viewer
Get Actionable Data in GubraView
Our cloud-based data viewer GubraView provides instant access to study data as it is uploaded, ensuring seamless monitoring throughout your study. With features for cross-group and cross-study comparisons, GubraView enables informed decision-making with statistical analyses. Accessible across multiple locations, GubraView empowers efficient and collaborative drug development for your whole team.
“
We are experts in bridging preclinical and clinical development.
ASBJØRN GRAVER PETERSEN Senior Scientist
Asbjørn focuses on idiopathic pulmonary fibrosis (IPF). He works closely with customers, drawing on his scientific background in fibrotic diseases and extensive experience in guiding the preclinical assessment of drug candidates from early discovery.
Are you interested to hear more?
Contact us
Gubra
Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650